HAG
VIVO

HighPoint Advisor Group’s Meridian Bioscience Inc VIVO Stock Holding History

HighPoint Advisor Group’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,305
Closed -$258K – 573
2021
Q1 		$258K Buy
+10,305
New +$245K 0.03% 402

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighPoint Advisor Group's VIVO Position: Q2 2021 in Review

HighPoint Advisor Group sold out of Meridian Bioscience Inc (VIVO) in Q2 2021, closing a stake of 10,305 shares — an estimated $258K sold.

HighPoint Advisor Group first reported a position in VIVO in Q1 2021 and held it in 1 quarter. The position peaked at $258K in Q1 2021. 189 funds tracked by Wall St. Rank hold VIVO as of Q2 2021.

  • HighPoint Advisor Group reported no remaining Meridian Bioscience Inc position as of Q2 2021 after selling out during the quarter.
  • HighPoint Advisor Group sold 10,305 Meridian Bioscience Inc shares in Q2 2021, an estimated $258K.
  • HighPoint Advisor Group first reported a position in Meridian Bioscience Inc in Q1 2021 and held it in 1 quarter.
  • HighPoint Advisor Group's Meridian Bioscience Inc position peaked at $258K in Q1 2021.
  • 189 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2021.

Based on HighPoint Advisor Group's 13F filing for Q2 2021, filed 29 Jul 2021.